^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jiataile (sacituzumab tirumotecan)

    i
    Other names: MK-2870, SKB 264, SKB264, sac-TMT, SKB-264, MK2870, MK 2870
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    3d
    A Phase II Exploratory Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination with Bevacizumab for Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Open-Label, Multicenter Clinical Trial (ChiCTR2500108816)
    P2, N=38, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical UniversitynThe First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliate | Initiation date: Sep 2025 --> Feb 2026
    Trial initiation date
    |
    Avastin (bevacizumab) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    3d
    Switching to Sacituzumab Govitecan Combined Toripalimab in TNBC Patients:Tumor Non-Response After the First Stage of NC A Single-Arm Clinical Study to Explore the Efficacy and Safety (ChiCTR2500112392)
    P=N/A, N=31, Not yet recruiting, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Loqtorzi (toripalimab-tpzi) • Trodelvy (sacituzumab govitecan-hziy) • Jiataile (sacituzumab tirumotecan)
    3d
    The Pilot Study on Sacituzumab tirumotecan (SKB264) for the Treatment of Recurrent Adamantinomatous Craniopharyngioma (ACP) (ChiCTR2500111542)
    P=N/A, N=12, Not yet recruiting, Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University
    New trial
    |
    Jiataile (sacituzumab tirumotecan)
    3d
    Clinical Study of ctDNA Dynamic Monitoring in Sacituzumab tirumotecan for EGFR-Mutated Non-Squamous NSCLC After EGFR-TKI Failure (ChiCTR2600115950)
    P4, N=30, Not yet recruiting, Shaanxi Provincial Cancer Hospital; Shaanxi Provincial Cancer Hospital
    New P4 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Jiataile (sacituzumab tirumotecan)
    3d
    Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combined With Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer (ChiCTR2500112194)
    P4, N=30, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P4 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    3d
    A Single-arm, Single-center Phase II Clinical Study of Sacituzumab tirumotecan Combined with Anlotinib in the Second-line Treatment of Patients with Advanced Gastric Cancer (ChiCTR2500112073)
    P4, N=33, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P4 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    3d
    Sintilimab Combined with Sacituzumab tirumotecan in Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Single-Arm, Single-Center, Phase II Clinical Study (ChiCTR2500111980)
    P4, N=49, Not yet recruiting, Tangdu Hospital, Fourth Military Medical University; Tangdu Hospital, Fourth Military Medical University
    New P4 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tyvyt (sintilimab) • Jiataile (sacituzumab tirumotecan)
    3d
    An Open-Label, Single-Center, Multi-Cohort, Phase II Study Evaluating the Safety and Efficacy of Vebreltinib-Based Combination Therapy in Previously Treated Patients with Locally Advanced or Metastatic MET-Overexpressing Non-Small Cell Lung Cancer (ChiCTR2500112942)
    P2, N=52, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • ALK rearrangement • MET exon 14 mutation • MET overexpression • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • MET mutation • MET expression • RET rearrangement • NTRK fusion
    |
    docetaxel • Jiataile (sacituzumab tirumotecan) • bozitinib (APL-101)
    3d
    An exploratory study of Sacituzumab Tirumotecan in the treatment of EGFR-mutated platinum-based chemotherapy-resistant transformed small cell lung cancer (ChiCTR2500113126)
    P2, N=39, Not yet recruiting, Dongguan People's Hospital; Dongguan People's Hospital
    New P2 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR positive
    |
    Jiataile (sacituzumab tirumotecan)
    3d
    A single-arm, phase II clinical study of Sacituzumab Tirumotecan combined with Bevacizumab for the treatment of platinum-resistant epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer (ChiCTR2500112955)
    P2, N=30, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan) • Lucentis (ranibizumab)
    3d
    Phase II Clinical Trial of Sacituzumab tirumotecan Combined with Cadonilimab as Second-Line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Single-Center Study (ChiCTR2600116847)
    P2, N=33, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New P2 trial
    |
    Kaitanni (cadonilimab) • Jiataile (sacituzumab tirumotecan)
    3d
    A prospective single-arm phase II clinical trial on the sacituzumab tirumotecan treatment of targeted therapy pre-treated, advanced or metastatic non-small cell lung cancer patients with EGFR uncommon mutations (ChiCTR2500114453)
    P2, N=30, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Jiataile (sacituzumab tirumotecan)